Research Reports on Healthcare Equities -- Endo, Teva Pharma Industries, Ionis Pharma, and Catalent

Sep 07, 2016, 07:35 ET from Chelmsford Park SA

NEW YORK, September 7, 2016 /PRNewswire/ --

Ahead of today's trading session, closely evaluates the recent performances of the following Healthcare equities: Endo International PLC (NASDAQ: ENDP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Catalent Inc. (NYSE: CTLT). Over the past five years, the MSCI All Country Healthcare index has outperformed the global stock market by over 60%. However, the outperformance has gradually decreased during the last 12 months. Learn more about these stocks by accessing their free research reports at:

Endo Intl. 

Dublin, Ireland headquartered Endo International PLC's shares rose 3.38% and finished Tuesday's trading session at $20.49. A total volume of 4.94 million shares was traded. In the last month and the previous three months, the stock has advanced 13.39% and 16.29%, respectively. The Company's shares are trading above their 50-day moving average by 7.62%. Moreover, shares of Endo International, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have a Relative Strength Index (RSI) of 48.66.

On August 12th, 2016, Endo International announced that based on a discussion with the U.S. Food and Drug Administration (FDA), the Company has decided to withdraw its supplemental New Drug Application (sNDA) relating to specific abuse deterrent labeling for OPANA® ER without prejudice to re-filing. The Company plans to continue collecting and analyzing epidemiological data relating to OPANA® ER. Endo's financial projections for 2016 did not assume approval of the sNDA.

On August 12th, 2016, research firm Mizuho upgraded the Company's stock rating from 'Neutral' to 'Buy'. The research firm also revised upwards its previous target price from $16 per share to $29 per share. Free research report on ENDP is available at:

Teva Pharma Industries  

On Tuesday, shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd recorded a trading volume of 7.24 million shares, which was above their three months average volume of 5.80 million shares. The stock ended the session 0.21% higher at $51.33. The Company's shares are trading 1.94% below their 50-day moving average. Furthermore, shares of Teva Pharmaceutical Industries, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have an RSI of 46.17.

On August 25th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $70 a share to $64 a share.

On August 30th, 2016, Teva Pharmaceutical announced that five company-sponsored abstracts will be presented at the 2016 European Respiratory Society International Congress in London, England on September 3-7, 2016. The presentations include new data on Teva's biologic CINQAERO® for severe eosinophilic asthma and the health economic impact of severe eosinophilic asthma. Of note, one of the abstracts will present a new analysis of CINQAERO® among the Global Initiative for Asthma (GINA) Step 4 and Step 5 patient groups. The complimentary research report on TEVA can be downloaded at:

Ionis Pharma  

Shares in Carlsbad, California headquartered Ionis Pharmaceuticals Inc. closed the day at $29.37, slightly down 0.31%. The stock recorded a trading volume of 1.65 million shares. The Company's shares have surged 31.53% in the previous three months, and are trading 1.50% below their 50-day moving average. Additionally, shares of Ionis Pharmaceuticals, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 38.85.

On August 9th, 2016, Ionis Pharmaceuticals reported revenue for the three months ended June 30th, 2016, of $38.5 million compared to $120.4 million for the same period in 2015. The company's net loss was $56.9 million for the three ended June 30th, 2016, compared to net income of $35.6 million for the same period in 2015.

On August 10th, 2016, research firm Piper Jaffray reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $36 a share to $46 a share. Visit us today and access our complete research report on IONS at:


At the closing bell yesterday, shares in Somerset, New Jersey headquartered Catalent Inc. ended 0.16% higher at $25.28 with a total trading volume of 718,651 shares. The stock has advanced 6.08% in the previous three months and 1.00% on an YTD basis. The Company's shares are trading above their 50-day moving average by 3.49%. Furthermore, shares of Catalent, which provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide, have an RSI of 56.88.

On September 6th, 2016, Catalent announced the launch of a secondary public offering of its common stock. Certain stockholders of Catalent are offering for sale to the public all of the approximately 19.0 million shares of Catalent's common stock owned by them. Catalent stated that it is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders. Get free access to your research report on CTLT at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA